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Genotyping experiments are widely used in clinical and basic research laboratories to 
identify associations between genetic variations and normal/abnormal phenotypes. 
Genotyping assay techniques vary from single genomic regions that are interrogated using 
PCR reactions to high throughput assays examining genome-wide sequence and structural 
variation. The resulting genotype data may include millions of markers of thousands of 
individuals, requiring various statistical, modeling or other data analysis methodologies to 
interpret the results. To date, there are no standards for reporting genotyping experiments. 
Here we present the Minimum  Information about a Genotyping Experiment (MIGen) 
standard, defining the minimum information required for reporting genotyping experiments. 
MIGen standard covers experimental design, subject description, genotyping procedure, 
quality control and data analysis. MIGen is a registered project under MIBBI (Minimum 
Information for Biological and Biomedical Investigations) and is being developed by an 
interdisciplinary group of experts in basic biomedical science, clinical science, biostatistics 
and bioinformatics. To accommodate the wide variety of techniques and methodologies 
applied in current and future genotyping experiment, MIGen leverages foundational concepts 
from the Ontology for Biomedical Investigations (OBI) for the description of the various types 
of planned processes and implements a hierarchical document structure. The adoption of 
MIGen by the research community will facilitate consistent genotyping data interpretation 
and independent data validation. MIGen can also serve as a framework for the development 
of data models for capturing and storing genotyping results and experiment metadata in a 
structured way, to facilitate the exchange of metadata. 
Introduction 
With the continued advances in genotyping 
technologies, especially high-throughput genotyping 
techniques, there is an exponential growth of genetic 
data in the biomedical literature [1]. This 
information forms a foundation for biomedical 
researchers to formulate new hypotheses about the 
molecular determinants of disease pathogenesis. 
However, the diversity between genotyping 
experiments, including experimental design, assay 
technique and data analysis method, makes data 
interpretation, validation and reproduction difficult 
to the end-users. The information reported in the 
literature for genotyping experiments is often 
insufficient, ambiguous and inconsistent. The 
research community lacks genotyping experiment 
reporting standards, so called minimum information 
checklist. 
A minimum information checklist specifies the 
minimum set of information required to describe 
experimental findings, such that reviewers and end-Huang et al. 
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users of the scientific publication can interpret and 
use  the experimental results unambiguously. The 
research community is increasingly in favor of 
application of minimum information checklists [2]. 
Successful implementation and adoption of 
minimum information checklists by journals and 
databases include the Minimum Information About a 
Microarray Experiment (MIAME) [3] and the 
Minimum Information about a Flow Cytometry 
Experiment (MIFlowCyt) [4] standards. Currently, 
there is no equivalent checklist for reporting 
genotyping experiments. To establish such standard, 
here we propose the Minimum Information about a 
Genotyping Experiment (MIGen). MIGen is 
developed to specify a set of minimum information 
that need to be provided by the author of a 
genotyping experiment, either when publishing in a 
journal article or when making data available in 
public databases. MIGen is a registered project 
under Minimum Information for Biological and 
Biomedical Investigations (MIBBI [5]), which 
coordinates the development of minimum 
information checklists for biological and biomedical 
research. 
MIGen is developed by cross-disciplinary experts in 
clinical and basic biological research, bioinformatics 
and biostatistics. It is proposed to the research 
community to collect comments and to reach 
consensus. 
Challenge of MIGen Development 
In MIGen, a genotyping experiment is defined as a 
study that is designed to elucidate some aspect of 
the genomic nucleotide sequence structure of an 
individual or group of individual organism(s). 
Genotyping experiments covered by MIGen are 
highly diverse in many aspects: 
•Genotyping experiment techniques 
are employed to accomplish different 
study purposes. They may be used as 
a primary discovery method, as in a 
genome-wide association study 
(GWAS), or to test the association or 
effect of specific sequence variants 
known to contribute to a phenotype 
of interest, as in studies utilizing 
animal model of disease. 
•Different types of genetic variants may 
be assayed in genotyping experiments, 
including single nucleotide 
polymorphisms (SNP), variable 
numbers of tandem repeats (e.g. 
microsatellites), copy number 
variation (CNV), genomic 
rearrangements, transgenes, gene 
knockout, etc.. Genotyping scale range 
from a small number of genomic 
variants genotyped in only a few 
biological samples to millions of 
variants assayed in thousands of 
samples. 
•Depending on the purpose of a 
genotyping study, the experimental 
design varies - population study 
versus familial study, prospective 
study versus retrospective study, etc. 
- requiring different subject selection 
criteria and different 
subject/population characteristics 
captured during the course of the 
study. 
•Genotyping assay techniques also 
differ substantially. They differ in 
their technical complexity and in the 
type of raw data generated. Assay 
techniques range from single PCR 
amplification assays to various high 
throughput approaches. The type of 
raw data generated also varies, for 
example, from Sanger sequencing 
technique which generates one 
chromatogram read per sample, to 
next generation sequencing methods 
which generate large numbers of 
short reads, provided as fluorescent 
image files. 
•Multiple data processing and analysis 
methods exist to accommodate the 
diversity between genotyping 
experiments. The data analysis 
procedures of a genotyping 
experiment may range from a simple 
call from a PCR amplicon size to a 
complex sequence of steps that may 
include quality control filtering, 
imputation, population stratification 
and statistical test. Minimum Information about a Genotyping Experiment 
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A minimum information checklist should be short 
and complete, so that it is convenient for users to 
follow, yet specifies all of the elements required to 
describe an experiment of the type. Given the 
diversity of genotyping experiments, as mentioned 
above, it is a significant challenge to develop MIGen 
as a concise but generalized guideline to suit all 
kinds of genotyping experiment reports. Moreover, 
genotyping technologies and their applications 
evolve rapidly, so MIGen should also be flexible to 
accommodate future genotyping technologies. 
MIGen Development Principles 
Components of MIGen 
MIGen was designed to be consistent with other 
well-established MIBBI projects, e.g. MIAME, 
MIFlowCyt and MISFISHIE [6]. 
MIGen consists of four sections: 
1. Experiment Overview 
specifies general information 
that should be provided for the 
overall experiment, e.g., 
experiment purpose, study 
personnel, study centers, etc. 
2. Experiment Subjects 
Description specifies 
information that should be 
provided to unambiguously 
interpret how the experimental 
subjects were recruited and 
selected, as well as subject and 
population characteristics 
collected during the study. 
3. Genotyping Procedure provides 
guidelines to report how 
biological samples were 
collected and processed from 
experimental subjects and how 
the raw data was generated. 
This section includes 
descriptions of the genomic 
variants assayed and 
descriptions of genotyping 
procedures and technologies. 
4. Data Transformation section 
includes specification for 
reporting the data processing 
and analysis methods. 
The first version of MIGen can be found on the 
MIGen website [7]. Like other MIBBI standards, we 
emphasize that MIGen specifies the minimum 
information that needs to be reported, but not the 
order or format of how the required information is 
provided. Therefore, when using the MIGen 
standard to guide the reporting of genotyping 
experiments, it is not necessary to organize the 
report following MIGen document structure. 
Moreover, MIGen states that one shall refer to the 
appropriate minimum information document if one 
exists for a specific experiment technique involved 
in the genotyping procedure, e.g., refer to the 
MIFlowCyt standard if a flow cytometry technique 
was used; refer to the MIAME standard if a 
microarray technique was used. 
Ontology for Biomedical Investigation 
application in MIGen 
Of the four  sections covered in MIGen, the first 
two sections are essentially applicable to all types 
of genotyping experiments and were relatively 
straightforward to develop. In contrast, because of 
the complex nature of genotyping assay 
techniques and various data analysis methods 
employed, the Genotyping Procedure and Data 
Transformation sections are the major challenge 
in MIGen development. To capture the common 
features of the Genotyping Procedure and Data 
Transformation sections for all genotyping 
experiments, MIGen applies the “planned process” 
concept from the Ontology for Biomedical 
Investigations (OBI) [8]. A planned process is a 
processual entity that realizes a plan, which is the 
concretization of a plan specification (ID: 
“obo:OBI_0000011”) [8]. There are three basic 
types of planned processes in OBI: biomaterial 
transformation, assay and data transformation, 
each of which is a process with three components: 
input, other participants and output, as illustrated 
in Figure 1. Huang et al. 
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The biomaterial transformation process is defined 
as an event with one or more biomaterials as inputs 
and outputs. For example, DNA extraction from a 
blood sample is a biomaterial transformation 
process, where blood is the input biological 
material, DNA is the output material and the DNA 
extraction reagents and devices used in the process 
are other participants. An assay is a planned 
process with the objective to produce information 
about some evaluant (ID: “obo:OBI_0000070”) [8]. 
It has biological material as input and data as 
output. For example, a microarray based 
genotyping assay has DNA as input and raw image 
data as output, where reagents, instruments and 
software utilized in the process are other 
participants. Starting with the raw data generated 
from the assay, we move to the data transformation 
processes. A data transformation process is a 
protocol application that produces output data 
from input data (ID: “obo:OBI_0200000”) [8]. 
 
Figure 1. Planned Processes 
 
With the application of OBI concepts in MIGen, 
genotyping procedure and data analysis 
components of a genotyping experiment are 
considered as a sequence of planned processes, 
each of which can be categorized as a biomaterial 
transformation, assay, or data transformation 
process. With this abstractive view, virtually all 
steps executed in any genotyping experiment can 
be easily and explicitly specified at a high level, 
describing what information is required to be 
reported, without enumerating all the varieties for 
any given step. For example, MIGen specifies that 
if the input is a biomaterial, one must provide 
information on its type, its amount in value-unit 
pair, and other significant attributes. For detailed 
specification, please refer to the MIGen 
documentation. 
The application of the OBI ontology within MIGen 
provides an abstractive framework that is 
generalized to define the necessary reporting 
standards for any process in a genotyping 
experiment. However, due to the complexity of 
genotyping experiments, there are many steps or 
processes involved, which can be reported at 
different levels of granularity depending on the 
experimenter’s definition of a process. For example, 
a PCR genotyping experiment can be broken down 
into sequential processes as following, starting from 
DNA sample: 1) biomaterial transformation  where 
DNA is the input and assembled PCR reaction mix is Minimum Information about a Genotyping Experiment 
228  Standards in Genomic Sciences 
the output, 2) biomaterial transformation  where 
DNA sample in the PCR reaction mix is the input, the 
amplified DNA amplicon is the output of the 
thermocycler reaction, 3) an assay  process where 
DNA amplicons are the input and the gel image is the 
output of the electrophoresis assay and 4) a data 
transformation process  where the gel image was 
analyzed to determine the size of the samples’ 
amplicon. Alternatively, an experimenter can define 
the entire chain of processes as a single assay 
process where DNA (biological material) is the input 
and the size of each samples’ amplicon (data) is the 
output. 
MIGen does not constrain how the experimenters 
break down the experimental or data analysis 
procedures, but rather specifies the list of key 
information that needs to be included to ensure the 
unambiguous interpretation, reproduction and 
reuse of the data. 
Hierarchical Structure of MIGen 
Unlike many existing minimum information 
checklists for other experimental domains, such as 
MIAME for microarray gene expression 
experiments and MIFlowCyt for flow cytometry 
experiments, where the experimental techniques 
and raw data are relatively comparable, the huge 
diversity of genotyping experiments makes it 
difficult to list all of the key information of each 
genotyping experiment, especially for the 
Genotyping Procedure section. The introduction of 
OBI concepts into MIGen development solves the 
problem of how to provide a generalized guideline 
for all types of genotyping experiments, although at 
the same time it implies that the experimenters 
need to make judgments on what key information 
need to be reported for each experiment. To make 
certain that MIGen serves well as a minimum 
information checklist to ensure key information 
availability for each type of genotyping experiment 
technique and data analysis procedure, MIGen is 
built as a hierarchically structured package, as 
illustrated in Figure 2. 
The top-level components in the hierarchy are the 
most general specification and are applicable to all 
different types of genotyping experiments, and are 
where OBI concepts are introduced. The next level 
components, which we call modules, inherit 
guidelines from the top-level specification with 
added concrete details of the particular 
experimental technique/analysis methods. This 
modular approach is mainly applied to the Genotype 
Procedure and Data Transformation sections of 
MIGen. With the hierarchical structure of MIGen, 
new modules can be added at anytime as the need 
arises for the research community. 
The top-level hierarchical components of MIGen are 
available to the research community at [7]. The 
development of each specific module is ongoing 
among the authors. 
 
Figure 2. Hierarchical structure of MIGen package Huang et al. 
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Discussion 
The efficient sharing and exchange of data rely on 
consistent data reporting standards, with which end-
users of the data can acquire an understanding of the 
data generation and analysis methods. With today’s 
high throughput genotyping technologies and large-
scale genomic studies, data reusability is critical for 
cost effective study design and meta-analyses of 
published genetic studies. The development and 
implementation of MIGen standards fills the gap 
between the initial genotyping experiment 
information providers and the genotyping data users. 
While MIGen follows the high-level structure of other 
well-established minimum information checklists, it 
also leverages foundational concepts from the OBI 
ontology. The use of planned processes and a 
hierarchical structure allows MIGen to accommodate 
the many varied and unique aspects of different 
genotyping experiments. A similar but distinct 
hierarchical architecture of checklists has been 
proposed by the Geomic Standards Consortium 
community, where the minimum information about 
any (x) sequence (MIxS) was created by reverse 
engineering an “overarching framework” [9] to serve 
as a single entry point for different technology-
specific checklists, such as Minimum information 
about a marker gene sequence (MIMARKS) [9], the 
minimum information about a genome sequence 
(MIGS) [10], etc. Independently developed checklists 
are collected under the MIxS, sharing the same central 
set of core descriptors but having checklist specific 
descriptors as well. The MIGen hierarchical 
architecture not only provides a means for all 
modules to share common high-level structure, but 
also the specifications provide the guidelines for 
development of each module. 
Further discussion within the research community 
must take place to reach the final consensus on the 
proposed standard. We welcome comments on the 
documentation and additions to the MIGen modules 
for specific genotyping experiment types. MIGen will 
facilitate data sharing in the research community, 
making independent data interpretation, validation 
and reproduction more efficient and unambiguous. 
MIGen can also serve as a framework for the 
development of data models to capture and store 
genotyping result data and experiment metadata in 
a structured way, to facilitate data exchange and 
sharing. 
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